Safe use of ibuprofen in COVID-19 in children




COVID-19, children, ibuprofen, review


The literature review presents current data on the use of ibuprofen in COVID-19. Features of оmicron-variant of the disease are presented, which, unlike previous outbreaks, has a very high level of transmission, shorter average incubation period, increased incidence among children. Because most children have mild to moderate COVID-19, nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, are the most commonly used drugs in childhood to relieve pain and fever. During the first outbreak of COVID-19, NSAID and ibuprofen have been suggested to be dangerous for use in COVID-19 because they may increase the risk of severe and fatal COVID-19 disease. Experimental and clinical data on the safe use of ibuprofen in COVID-19 are presented. To date, there is no increased risk of COVID-19 infection with ibuprofen. In addition, there was no increased risk of hospitalization or severe COVID-19, death of patients taking ibuprofen. A lower risk of death has been found in patients with COVID-19 who received NSAIDs, consistent with a reduction in inflammation and a cytokine storm in severe COVID-19 and a protective role for NSAIDs. According to the Protocol ”Provision of medical care for the treatment of coronary heart disease ­(COVID-19)“ in mild to moderate disease in children, symptomatic treatment of fever and pain with ibuprofen is indicated. Thus, according to WHO guidelines and available clinical data, ibuprofen can be safely used for analgesic and antipyretic effects in children with COVID-19.


Download data is not yet available.


Grabowski F, Kochańczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion. Viruses. 2022 Jan 30;14(2):294. doi: 10.3390/v14020294.

Ferguson N, Ghani A, Cori A, et al. Report 49: Growth, population distribution and immune escape of the Omicron in England. Imperial College London. 2021. doi: 10.25561/93038.

Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2022 Jan 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.

World Health Organization. Update on omicron. 2021 Nov 28. Available from:

Jansen L, Tegomoh B, Lange K, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1782-1784. doi: 10.15585/mmwr.mm705152e3. 

Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Preprint]. 2022 Jan 2:2021.12.30.21268495. doi: 10.1101/2021.12.30.21268495.

Singhal T. The Emergence of Omicron: Challenging Times Are Here Again! Indian J Pediatr. 2022 May;89(5):490-496. doi: 10.1007/s12098-022-04077-4.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020 Mar 17;94(7):e00127-20. doi: 10.1128/JVI.00127-20.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8.

Micallef J, Soeiro T, Jonville-Béra AP; French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020 Jul-Aug;75(4):355-362. doi: 10.1016/j.therap.2020.05.003.

Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does Ibuprofen Worsen COVID-19? Drug Saf. 2020 Jul;43(7):611-614. doi: 10.1007/s40264-020-00953-0.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.

Sodhi M, Etminan M. Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded? Chest. 2020 Jul;158(1):55-56. doi: 10.1016/j.chest.2020.03.040.

Krenke K, Krawiec M, Kraj G, Peradzynska J, Krauze A, Kulus M. Risk factors for local complications in children with community-acquired pneumonia. Clin Respir J. 2018 Jan;12(1):253-261. doi: 10.1111/crj.12524.

Messika J, Sztrymf B, Bertrand F, et al. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care. 2014 Oct;29(5):733-8. doi: 10.1016/j.jcrc.2014.05.021.

Kotsiou OS, Zarogiannis SG, Gourgoulianis KI. Prehospital NSAIDs use prolong hospitalization in patients with pleuro-pulmonary infection. Respir Med. 2017 Feb;123:28-33. doi: 10.1016/j.rmed.2016.12.005.

Chen JS, Alfajaro MM, Chow RD, et al. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J Virol. 2021 Jan 13;95(7):e00014-21. doi: 10.1128/JVI.00014-21.

Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology. 2020 Dec;28(6):1477-1480. doi: 10.1007/s10787-020-00755-x.

Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021 Jan;133:110982. doi: 10.1016/j.biopha.2020.110982.

World Health Organization. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. 2020 19 Apr. Available from:

World Health Organization. Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms. 2020. Available from:

National Institute for Health and Care Excellence. 2020. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. Available from:

Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ. 2020 Apr 17;369:m1555. doi: 10.1136/bmj.m1555.

EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. 2020. Available from:

U.S. Food and Drug Administration. FDA Advises Patients on Use of NSAIDs for COVID-19. United States of America: FDA; 2020. Available from:

Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97-106. doi: 10.1159/000375362.

Micallef J, Soeiro T, Jonville-Béra AP. COVID-19 and NSAIDs: Primum non nocere. Therapie. 2020 Sep-Oct;75(5):514-515. doi: 10.1016/j.therap.2020.07.008.

Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 May 14;41(19):1801-1803. doi: 10.1093/eurheartj/ehaa235.

Trifirò G, Crisafulli S, Andò G, Racagni G, Drago F; Italian Society of Pharmacology. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf. 2020 Jun;43(6):507-509. doi: 10.1007/s40264-020-00935-2.

Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, Eisenbarth SC, Wilen CB. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. bioRxiv [Preprint]. 2020 Sep 25:2020.09.24.312769. doi: 10.1101/2020.09.24.312769.

Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C. NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Saf. 2021 Sep;44(9):929-938. doi: 10.1007/s40264-021-01089-5.

Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. Infect Dis Ther. 2021 Mar;10(1):253-268. doi: 10.1007/s40121-020-00363-w.

Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020 Sep;26(9):1259.e5-1259.e7. doi: 10.1016/j.cmi.2020.06.003.

Chandan JS, Zemedikun DT, Thayakaran R, et al. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis Rheumatol. 2021 May;73(5):731-739. doi: 10.1002/art.41593.

Prada L, D Santos C, Baião RA, Costa J, Ferreira JJ, Caldeira D. Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis. J Clin Pharmacol. 2021 Dec;61(12):1521-1533. doi: 10.1002/jcph.1949.

Martins-Filho PR, do Nascimento-Júnior EM, Santos VS. No current evidence supporting risk of using Ibuprofen in patients with COVID-19. Int J Clin Pract. 2020 Oct;74(10):e13576. doi: 10.1111/ijcp.13576.

Varrassi G. Warning Against the Use of Anti-Inflammatory Medicines to Cure COVID-19: Building Castles in the Air. Adv Ther. 2020 May;37(5):1705-1707. doi: 10.1007/s12325-020-01321-1.

Capuano A, Scavone C, Racagni G, Scaglione F; Italian Society of Pharmacology. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? Pharmacol Res. 2020 Jul;157:104849. doi: 10.1016/j.phrs.2020.104849.

Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience. Canadian Journal of Medicine. 2021;3(3):121-143. doi: 10.33844/cjm.2021.60511.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2.

Herzberg DL, Sukumaran HP, Viscusi E. NSAIDs for analgesia in the era of COVID-19. Reg Anesth Pain Med. 2020 Sep;45(9):677-678. doi: 10.1136/rapm-2020-101584.

Mishra P, Tomar A, Kumar A, Nath A, Sharma SK, Singh GK. Pain management in COVID-19 pediatric patients-An evidence- based review. Saudi J Anaesth. 2021 Jan-Mar;15(1):33-39. doi: 10.4103/sja.SJA_635_20.

Esposito S, Abate L, Laudisio SR, et al. COVID-19 in Children: Update on Diagnosis and Management. Semin Respir Crit Care Med. 2021 Dec;42(6):737-746. doi: 10.1055/s-0041-1741371.

Vosu J, Britton P, Howard-Jones A, et al. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19? J Paediatr Child Health. 2020 Oct;56(10):1645-1646. doi: 10.1111/jpc.15159.

Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010 Mar;44(3):489-506. doi: 10.1345/aph.1M332.

Jin J., Wang X., Wang J., Wan Z. Efficacy and safety of ibuprofen in children with musculoskeletal injuries: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021 Jul 2. 100(26). e26516. doi: 10.1097/MD.0000000000026516. 

Parri N., Lazzeri S. Efficacy of ibuprofen in musculoskeletal post-traumatic pain in children: A systematic review. PLoS One. 2020 Dec 3. 15(12). e0243314. doi: 10.1371/journal.pone.0243314. 

NICE Guideline Updates Team (UK). Fever in under 5s: assessment and initial management. London: National Institute for Health and Care Excellence (UK); 2019. Available from:

Chiappini E, Venturini E, Remaschi G, et al; Italian Pediatric Society Panel for the Management of Fever in Children. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J Pediatr. 2017 Jan;180:177-183.e1. doi: 10.1016/j.jpeds.2016.09.043.

Green C, Krafft H, Guyatt G, Martin D. Symptomatic fever management in children: A systematic review of national and international guidelines. PLoS One. 2021 Jun 17;16(6):e0245815. doi: 10.1371/journal.pone.0245815.

de Martino M, Chiarugi A, Boner A, Montini G, De' Angelis GL. Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal. Drugs. 2017 Aug;77(12):1295-1311. doi: 10.1007/s40265-017-0751-z.

MOH of Ukraine. Protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" of February 22, 2022 № 358. Available from:



How to Cite

Borysova, T. (2022). Safe use of ibuprofen in COVID-19 in children. CHILD`S HEALTH, 17(1), 54–58.



Review of Literature

Most read articles by the same author(s)

1 2 3 4 > >>